JAC Advance Access originally published online on January 6, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 464-465
© 2003 The British Society for Antimicrobial Chemotherapy
Correspondence |
Reply
Department of Medical Microbiology, Faculties of 1 Medicine and 3 Pharmacy, University of Manitoba, Manitoba; Departments of 2 Clinical Microbiology and 4 Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada
Keywords: dual activity, fluoroquinolones
| The first 10% of the full text of this article appears below. |
Sir,
The letter by Fisher & Heaton1 discusses many important considerations in the study of dual activity in fluoroquinolones, i.e. that enzymic and genetic studies evaluate different components in the activity of fluoroquinolones and that only proper understanding and use of fluoroquinolones will limit the emergence of clinical resistance. As Fisher
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. M. Fisher, K. A. Gould, X.-S. Pan, S. Patel, and V. J. Heaton Analysis of dual active fluoroquinolones in Streptococcus pneumoniae J. Antimicrob. Chemother., August 1, 2003; 52(2): 312 - 313. [Full Text] [PDF] |
||||
![]() |
H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel Reply J. Antimicrob. Chemother., August 1, 2003; 52(2): 313 - 314. [Full Text] [PDF] |
||||
